Please login to the form below
Terrosa
This page shows the latest Terrosa news and features for those working in and with pharma, biotech and healthcare.
CHMP recommends Merck & Co's Lantus biosimilar
Hungarian pharmaceutical firm Gedeon Richter and Germany's Stada Arzneimittel received recommendations for Terrosa and Movymia respectively, for the treatment of postmenopausal women and men at increased risk of fracture.
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Rare diseases: not so rare after all
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
PMHub
Say Communications
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
